JANX Trading Analysis - 10/22/2026 02:23 PM — TRU-SENTIMENT

News Headlines & Context

Recent general knowledge context for JANX (Janux Therapeutics, a clinical-stage immunotherapy biotech):

• JANX presented interim Phase 1 data for its TNFR2 agonist in solid tumors at a major oncology conference, showing tolerability but early efficacy signals.
• Company disclosed a secondary equity offering earlier in 2026, contributing to share dilution and downward pressure on stock.
• No near-term FDA approval catalysts scheduled; pipeline milestones expected mid-to-late 2027.
• Biotech sector weakness and high-beta small caps underperforming broader market in Oct 2026.
• Context: Headlines reflect early-stage risk and dilution concerns, which align with the bearish options flow and negative EPS in fundamentals data below.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data:

• Trailing EPS is -1.64; company is not profitable (no trailingPE or forwardPE available, both null).
• Market cap is $1,032,909,615 with 61,137,000 shares outstanding.
• Dividend yield 0.0%; no dividend declared.
• Beta is 3.70 indicating high systemic risk vs market.
• 52-week range: $12.12 low to $35.34 high; current price ~$16.97 sits in lower third of range.
• Institutional ownership 42.41%; average volume 827,000.
• Historical volatility 53.16% — elevated.
• Revenue growth, margins, ROE, D/E, FCF all null — not disclosed in data.
• Analyst target mean price and recommendation key null — no consensus in data.
• Fundamentals (negative earnings, high beta, no profitability) diverge from any bullish technical bounce and align with bearish sentiment flow.

Current Market Position

Current price per indicators is $16.97 (as of 2026-10-21 close). Minute bars show 2026-10-21 open $17.22, high $17.47, low $16.79, close $16.97. On 2026-10-22 at 13:55, last bar close $16.90 (open $16.88, high $16.90, low $16.88). Intraday on 10-22 drifted from ~$16.68 to $16.90, mild recovery but below prior day close.

Technical Analysis

Price $16.97 is below SMA 5 ($16.95? actually 16.95 is below 16.97 slightly — price above SMA5 by $0.02), below SMA20 ($17.15) and below SMA50 ($17.52): bearish alignment. SMA order: SMA5 < SMA20 < SMA50, confirming downtrend. RSI 50.79 neutral. MACD -0.05 below signal -0.04, histogram -0.01 = mild bearish. Bollinger: price inside bands, near lower-middle. 30d range high $19.33, low $15.75; price at 31% of range ((16.97-15.75)/(19.33-15.75)=0.31).

True Sentiment Analysis (Delta 40-60 Options)

Options flow (Delta 40-60 only): Call dollar vol $115,430 (6.7%), Put dollar vol $1,613,870 (93.3%), total $1,729,300. Sentiment: Bearish. 3 call trades vs 12 put trades; 586 call contracts vs 2354 put contracts. Pure directional conviction strongly bearish — puts dominate by 14x dollar vol. This aligns with technical downtrend and negative fundamentals; no divergence observed.

Full chain: JANX Options Flow

Key Price Levels (Observational Only)